NDATOPICALCREAM
Approved
Dec 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
ELIDEL (pimecrolimus) by Bausch + Lomb is calcineurin inhibitors [moa]. Approved for calcineurin inhibitor immunosuppressant [epc]. First approved in 2001.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ELIDEL (pimecrolimus) is a topical calcineurin inhibitor cream approved in 2001 for atopic dermatitis and multiple other inflammatory skin conditions. It works by suppressing T-cell activation and cytokine release at the site of inflammation without causing skin atrophy. The drug is indicated for conditions including prurigo nodularis, lichen sclerosus, chronic hand dermatitis, and vitiligo vulgaris.
$0.87MPart D
LOE ApproachingDeclining
As a mature product approaching loss of exclusivity with only $0.87M in Part D spending, the brand team is likely focused on maintenance and cost-efficiency rather than growth initiatives.
Mechanism of Action
Calcineurin Inhibitors
Pharmacologic Class:
Calcineurin Inhibitor Immunosuppressant
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Effect of Pimecrolimus Cream on Cathelicidin Levels in Subjects With Eczema
Started Oct 2009
40 enrolled
Atopic Dermatitis
A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis
Started May 2007
113 enrolled
Seborrheic Dermatitis
Evaluation of the Antipruritic Effect of Elidel (Pimecrolimus) in Non-atopic Pruritic Disease
Started Apr 2007
30 enrolled
Prurigo Nodularis
Study of Pimecrolimus Treatment for Atopic Dermatitis of African American Children
Started Nov 2006
18 enrolled
Atopic Dermatitis
Clobetasol Versus Pimecrolimus for Vulvar Lichen Sclerosus
Started Oct 2006
38 enrolled
Lichen Sclerosus
Worked on ELIDEL at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.